Swiss Re AG (SREN) Q2 2026 Earnings Report

The call presented a predominantly positive operational and financial picture: strong H1 profitability (USD 2.8bn net income), high ROE (23%), excellent P&C underwriting (76.7% combined ratio), robust Life & Health results, solid investment returns (4.0% ROI), and very strong capital metrics (SST ~264%). Management also highlighted disciplined cycle management, increased cost-savings targets (USD 500m), and prudent reserving actions that reinforce balance sheet resilience. Offsetting these positives are meaningful declines in new business CSM across divisions (notably Life & Health), pricing and competitive pressures in particular lines (nonproportional property, specialty), a risk-adjusted price decline explained by higher loss assumptions (~4.4%), an upward trend in expense ratios, and the risk that benign nat cat experience in H1 may not persist into peak hurricane season. Overall, the positives (profitability, capital strength, underwriting performance and active prudence) outweigh the headwinds from new-business profitability and line-specific pricing pressure, though these headwinds warrant monitoring.

The call reiterated clear 2026 targets and near‑term guidance: a full‑year net income target of USD 4.5bn (H1 net income USD 2.8bn, >60% of target) and a group ROE of 23% in H1, with Life & Health Re targeting USD 1.7bn net income for 2026 (L&H H1 net income just over USD 1bn; insurance service result USD 1.2bn; CSM release USD 758m, ~9% annualized; new business CSM USD 338m vs USD 569m prior), P&C Re delivering an H1 insurance service result of USD 1.8bn and a combined ratio of 76.7% (full‑year target <85%; new business CSM USD 1.6bn vs USD 2.2bn prior), and Corporate Solutions reporting an H1 combined ratio of 86.1% (insurance service result USD 578m; CSM release ~USD 400m; new business CSM USD 201m vs USD 262m). Management flagged key balance sheet and capital metrics: estimated group SST ~264% (up 14ppt since Jan 1, 2026, including a ~5ppt temporary benefit from subordinated debt), a USD 1.5bn share buyback ~60% executed by end‑July, investment ROI 4.0% with recurring income USD 2bn in H1, and an increased operating cost‑reduction target of USD 500m run‑rate by end‑2028 (reflecting progress on the prior USD 300m by 2027). On market and portfolio guidance they noted midyear renewals volume +11% vs business up for renewal (YTD premium volume +0.5%), nominal pricing broadly flat YTD (non‑prop property down high single digits, casualty mid‑single‑digit increases), year‑to‑date loss assumption increases of ~4.4% (risk‑adjusted price decline ~4.6%) and favorable nat‑cat experience ~USD 676m below expectations in H1 (with >USD 1bn short‑tail reserve releases and ~USD 500m added to long‑tail IBNR), and management reiterated confidence in staying below the P&C Re combined‑ratio target and in the group’s capitalization and cycle‑management strategy.